All In Biotech

Drug Trial Radar · NCT00492258

Sorafenib in Treating Patients at Risk of Relapse After Undergoing Surgery to Remove Kidney Cancer

SORCE: A Phase III Randomised Double-Blind Study Comparing Sorafenib With Placebo in Patients With Resected Primary Renal Cell Carcinoma at High or Intermediate Risk of Relapse

Last checked: Nov 20, 2026Latest source record: Aug 12, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,656 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,656

Planned (sponsor's estimate)

Start

Jun 2007

Primary completion

Aug 2012

Study completion Dec 2012

Sponsor

Lead sponsor
Medical Research CouncilGovernment (non-federal)
Sponsor type
Government (non-federal)
First posted
Jun 27, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving sorafenib after surgery may kill any tumor cells that remain after surgery. It is not yet known whether sorafenib is more effective than a placebo in treating kidney cancer. PURPOSE: This randomized phase III trial is studying sorafenib to see how well it works compared with a placebo in treating patients at risk of relapse after undergoing surgery to remove kidney cancer.

Conditions

  • Kidney Cancer

Interventions

  • sorafenib tosylateDrug

  • adjuvant therapyProcedure

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Disease-free survival

Locations

39 sites in 1 country. Site status is shown where the registry gives one.

  • Royal Bournemouth Hospital

    Bournemouth, England, United Kingdom

  • Bristol Haematology and Oncology Centre

    Bristol, England, United Kingdom

  • Queen's Hospital

    Burton-on-Trent, England, United Kingdom

  • Addenbrooke's Hospital

    Cambridge, England, United Kingdom

  • Gloucestershire Oncology Centre at Cheltenham General Hospital

    Cheltenham, England, United Kingdom

  • Derbyshire Royal Infirmary

    Derby, England, United Kingdom

  • Dorset County Hospital

    Dorchester, England, United Kingdom

  • Gloucestershire Royal Hospital

    Gloucester, England, United Kingdom

  • Diana Princess of Wales Hospital

    Grimsby, England, United Kingdom

  • Princess Royal Hospital at Hull and East Yorkshire NHS Trust

    Hull, England, United Kingdom

  • Ipswich Hospital

    Ipswich, England, United Kingdom

  • Leeds Cancer Centre at St. James's University Hospital

    Leeds, England, United Kingdom

  • Leicester Royal Infirmary

    Leicester, England, United Kingdom

  • Lincoln County Hospital

    Lincoln, England, United Kingdom

  • Saint Bartholomew's Hospital

    London, England, United Kingdom

  • Medical Research Council Clinical Trials Unit

    London, England, United Kingdom

  • Guy's Hospital

    London, England, United Kingdom

  • Royal Marsden - London

    London, England, United Kingdom

  • Charing Cross Hospital

    London, England, United Kingdom

  • Maidstone Hospital

    Maidstone, England, United Kingdom

  • Christie Hospital

    Manchester, England, United Kingdom

  • Clatterbridge Centre for Oncology

    Merseyside, England, United Kingdom

  • James Cook University Hospital

    Middlesbrough, England, United Kingdom

  • Northern Centre for Cancer Treatment at Newcastle General Hospital

    Newcastle upon Tyne, England, United Kingdom

  • Mount Vernon Cancer Centre at Mount Vernon Hospital

    Northwood, England, United Kingdom

  • Derriford Hospital

    Plymouth, England, United Kingdom

  • Dorset Cancer Centre

    Poole Dorset, England, United Kingdom

  • Portsmouth Oncology Centre at Saint Mary's Hospital

    Portsmouth Hants, England, United Kingdom

  • Whiston Hospital

    Prescot Merseyside, England, United Kingdom

  • Berkshire Cancer Centre at Royal Berkshire Hospital

    Reading, England, United Kingdom

  • Scarborough General Hospital

    Scarborough, England, United Kingdom

  • Scunthorpe General Hospital

    Scunthorpe, England, United Kingdom

  • Cancer Research Centre at Weston Park Hospital

    Sheffield, England, United Kingdom

  • Wexham Park Hospital

    Slough, Berkshire, England, United Kingdom

  • Southampton General Hospital

    Southampton, England, United Kingdom

  • University Hospital of North Staffordshire

    Stoke-on-Trent, England, United Kingdom

  • Torbay Hospital

    Torquay, England, United Kingdom

  • Aberdeen Royal Infirmary

    Aberdeen, Scotland, United Kingdom

  • Velindre Cancer Center at Velindre Hospital

    Cardiff, Wales, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.